Sagimet Biosciences Inc. (SGMT): who owns it and who trades it
As of Nov 16, 2026, SGMT insiders reported 10 open-market sales worth $4.9M and no purchases in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was George Kemble (Chair), with $4.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Sagimet Biosciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SGMT
122 funds and institutions reported SGMT shares worth $396M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $50.8M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 6.58M | – | $50.8M | +722% |
| Balyasny Asset Management L.P. | 3.63M | – | $28M | New |
| Woodline Partners LP | 3.00M | – | $23.2M | +200% |
| Silverarc Capital Management, LLC | 2.93M | – | $22.6M | New |
| Vanguard Capital Management LLC | 2.57M | – | $19.8M | +134% |
| Caligan Partners LP | 2.50M | – | $19.3M | New |
| Bvf Inc | 2.50M | – | $19.3M | New |
| Affinity Asset Advisors, LLC | 2.50M | – | $19.3M | +188% |
| Federated Hermes, Inc. | 2.09M | – | $16.1M | +267085% |
| Great Point Partners LLC | 2.03M | – | $15.7M | New |
| State Street Corp | 2.00M | – | $15.4M | +1449% |
| Saturn V Capital Management LP | 1.48M | – | $11.4M | New |
| Geode Capital Management, LLC | 1.44M | – | $11.2M | +367% |
| Blue Owl Capital Holdings LP | 1.26M | – | $9.7M | +278% |
| Baker Bros. Advisors LP | 952,996 | – | $7.4M | No change |
| Millennium Management LLC | 937,025 | – | $7.2M | +9% |
| Aberdeen Group plc | 847,700 | – | $6.6M | New |
| Goldman Sachs Group Inc | 759,086 | – | $5.9M | +348% |
| Hhlr Advisors, Ltd. | 724,800 | – | $5.6M | No change |
| Ameriprise Financial Inc | 581,217 | – | $4.5M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SGMT insiders reported $0 of open-market purchases and $4.9M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | George Kemble | Director | Sale | 350,987 | $10.23 | $3.6M | Form 4 |
| Aug 11, 2026 | George Kemble | Director | Sale | 20,206 | $9.95 | $201K | Form 4 |
| Jul 20, 2026 | David Happel | CEO | Sale | 64,051 | $7.76 | $497K | Form 4 |
| Jul 20, 2026 | Elizabeth Rozek | Chief Legal & Admin. Off | Sale | 10,545 | $7.76 | $81.8K | Form 4 |
| Jul 20, 2026 | George Kemble | Director | Sale | 18,844 | $7.46 | $141K | Form 4 |
| Feb 10, 2026 | David Happel | CEO | Sale | 12,101 | $5.36 | $64.9K | Form 4 |
| Feb 10, 2026 | Thierry Chauche | CFO | Sale | 1,312 | $5.36 | $7K | Form 4 |
| Feb 10, 2026 | Eduardo Bruno Martins | Chief Medical Officer | Sale | 3,640 | $5.36 | $19.5K | Form 4 |
| Feb 10, 2026 | Elizabeth Rozek | Chief Legal & Admin. Off | Sale | 2,622 | $5.36 | $14.1K | Form 4 |
| Nov 20, 2025 | George Kemble | Chair | Sale plan | 37,688 | $7.69 | $290K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George Kemble | Executive Chairman, Director | – | $4.2M | Aug 14, 2026 |
| David Happel | President & CEO, Director | – | $562K | Jul 20, 2026 |
| Elizabeth Rozek | Chief Legal & Admin. Officer | – | $95.9K | Jul 20, 2026 |
| Eduardo Bruno Martins | Chief Medical Officer | – | $19.5K | Feb 10, 2026 |
| Thierry Chauche | Chief Financial Officer | – | $7K | Feb 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SGMT short interest
12.17M SGMT shares are sold short. Over the last 12 reports the number of shares short went up 189%.
As of Oct 30, 2026, 12.17M SGMT shares were sold short, up 5.6% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.17M | – | +6% | 1.16M | 10.5 |
| Oct 15, 2026 | 11.53M | – | +3% | 1.40M | 8.2 |
| Sep 30, 2026 | 11.19M | – | +9% | 1.67M | 6.7 |
| Sep 15, 2026 | 10.26M | – | +1% | 971,533 | 10.6 |
| Aug 31, 2026 | 10.11M | – | -14% | 1.06M | 9.6 |
| Aug 14, 2026 | 11.75M | – | +1% | 1.71M | 6.9 |
| Jul 31, 2026 | 11.60M | – | +19% | 711,090 | 16.3 |
| Jul 15, 2026 | 9.74M | – | +18% | 1.06M | 9.2 |
| Jun 30, 2026 | 8.25M | – | +42% | 2.10M | 3.9 |
| Jun 15, 2026 | 5.83M | – | +21% | 646,937 | 9.0 |
| May 29, 2026 | 4.80M | – | +14% | 826,148 | 5.8 |
| May 15, 2026 | 4.21M | – | -7% | 985,380 | 4.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Sagimet Biosciences company events
Sagimet Biosciences filed 17 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 22, 2026.
- Oct 22, 2026AnnouncementShared information with investors. Filing
- Oct 1, 2026AgreementSagimet Biosciences Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of the several underwriters named therein relating to an underwritten offering of (i) 8,750,010 shares of the Company’s Series A… Filing
- Sep 30, 2026AnnouncementThe Company issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China. Filing
- Aug 13, 2026AnnouncementSagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical trial of fatty acid synthase inhibitor denifanstat in moderate to severe acne. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 21, 2026AnnouncementShared information with investors. Filing
- Jun 12, 2026LeadershipTim Walbert, a member of the Board of Directors of Sagimet Biosciences Inc., tendered his resignation from the Board, effective as of June 12, 2026. Filing
- Jun 3, 2026LeadershipThe Compensation Committee of the Board of Directors of Sagimet Biosciences Inc. and the Board, as applicable, granted options to purchase shares of the Company’s Series A common stock, par value $0.0001 per share, and performance-based restricted stock units to David Happel, the Company’s… Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 28, 2026AgreementSagimet Biosciences Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein relating to an underwritten offering of 29,166,700 shares of the Company’s Series A common… Filing
- Apr 27, 2026AnnouncementShared information with investors. Filing
- Apr 27, 2026AnnouncementThe Company issued a press release announcing certain strategic and corporate updates. Filing
- Apr 21, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Mar 11, 2026ResultsReleased financial results. Filing
- Feb 2, 2026AnnouncementShared information with investors. Filing
- Dec 18, 2025AnnouncementThe Company issued a press release announcing positive results in the Phase 1 pharmacokinetic trial of a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, and a thyroid hormone receptor beta agonist, resmetirom. Filing
- Dec 17, 2025AnnouncementSagimet Biosciences Inc. issued a press release announcing its entry into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries Ltd. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sagimet Biosciences financials
Famous investors that hold SGMT
4 of the 50 well-known investors we track reported holding SGMT in their latest 13F filing. The largest position is Israel Englander's, worth $4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 406,857 | $4M | 0.0% | -57% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 133,079 | $1.3M | 0.0% | +27% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 89,700 | $886K | 0.0% | -74% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 35,629 | $352K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named SGMT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Woodline Partners LP | 13G | 5.1% |
| Nov 16, 2026 | Woodline Partners LP | 13G | 5.1% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 9.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 9.0% |
| Nov 13, 2026 | SilverArc Capital Management, LLC | 13G | 6.1% |
| Nov 13, 2026 | SilverArc Capital Management, LLC | 13G | 6.1% |
| Oct 7, 2026 | Commodore Capital LP | 13G | 7.6% |
| Oct 7, 2026 | Commodore Capital LP | 13G | 7.6% |
Questions about Sagimet Biosciences Inc. (SGMT) stock
Who owns the most SGMT stock?
The largest reported owner of Sagimet Biosciences Inc. (SGMT) is BlackRock, Inc.. In total, 122 funds and institutions reported holding SGMT at the end of Q2 2026. See the largest owners.
Are SGMT insiders buying or selling?
In the last 12 months, SGMT insiders reported no open-market purchases and 10 sales worth $4.9M. The latest trade was on Aug 14, 2026. See every trade.
What is the short interest in SGMT?
As of Oct 30, 2026, 12.17M SGMT shares were sold short, up 5.6% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold SGMT?
4 of the 50 well-known investors we track reported SGMT in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.